Since both drug enantiomers were used at their maximally effective doses and both were active iNOS inhibitors, we could not assess the relative contribution of iNOS and CB1R components of MRI-1867 to endotoxemia and intestinal permeability, which would require the drug to be administered at submaximal doses. Here, NOS2 is linked to serum lipopolysaccharide activity.